TCM
RIGL icon

Tekla Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Tekla Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-82,710
Closed -$2.76M – 64
2013
Q2 		$2.76M Buy
+82,710
New +$3.75M 0.38% 49

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Tekla Capital Management's RIGL Position: Q3 2013 in Review

Tekla Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2013, closing a stake of 82,710 shares — an estimated $2.76M sold.

Tekla Capital Management first reported a position in RIGL in Q2 2013 and held it in 1 quarter. The position peaked at $2.76M in Q2 2013. 95 funds tracked by Wall St. Rank hold RIGL as of Q3 2013.

  • Tekla Capital Management reported no remaining Rigel Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Tekla Capital Management sold 82,710 Rigel Pharmaceuticals shares in Q3 2013, an estimated $2.76M.
  • Tekla Capital Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Tekla Capital Management's Rigel Pharmaceuticals position peaked at $2.76M in Q2 2013.
  • 95 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2013.

Based on Tekla Capital Management's 13F filing for Q3 2013, filed 30 Oct 2013.